References
- Owen RG, Treon SP, Al-Katib A, et al. Clinicopathological definition of Waldenstrom’s macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom’s macroglobulinemia. Semin Oncol. 2003;30(2):110–115.
- Wang H, Chen Y, Li F, et al. Temporal and geographic variations of Waldenstrom macroglobulinemia incidence: a large population-based study. Cancer. 2012;118(15):3793–3800.
- Leblond V, Kastritis E, Advani R, et al. Treatment recommendations from the Eighth International Workshop on Waldenstrom’s macroglobulinemia. Blood. 2016;128(10):1321–1328.
- Rourke M, Anderson KC, Ghobrial IM. Review of clinical trials conducted in Waldenstrom macroglobulinemia and recommendations for reporting clinical trial responses in these patients. Leuk Lymphoma. 2010;51(10):1779–1792.
- Leblond V, Johnson S, Chevret S, et al. Results of a randomized trial of chlorambucil versus fludarabine for patients with untreated Waldenstrom macroglobulinemia, marginal zone lymphoma,or lymphoplasmacytic lymphoma. J Clin Oncol. 2013;31(3):301–307.
- Oza A, Rajkumar SV. Waldenstrom macroglobulinemia: prognosis and management. Blood Cancer J. 2015;5(3):e394–e394.
- Dimopoulos MA, Tedeschi A, Trotman J, et al. Phase 3 trial of ibrutinib plus rituximab in Waldenström's macroglobulinemia. N Engl J Med. 2018;378(25):2399–2410.
- Morel P, Duhamel A, Gobbi P, et al. International prognostic scoring system for Waldenstrom macroglobulinemia. Blood. 2009;113(18):4163–4170.
- Kastritis E, Morel P, Duhamel A, et al. A revised international prognostic score system for Waldenström’s macroglobulinemia. Leukemia. 2019;33(11):2654–2661.
- Shuhua Y, Rui C, Zengjun L, et al. Distinct characteristics and new prognostic scoring system for Chinese patients with Waldenström macroglobulinemia. Chin Med J (Engl). 2014;127:2327–2331.
- Cao XX, Meng Q, Cai H, et al. Detection of MYD88 L265P and WHIM-like CXCR4 mutation in patients with IgM monoclonal gammopathy related disease. Ann Hematol. 2017;96(6):971–976.
- Iwanaga M, Chiang CJ, Soda M, et al. Incidence of lymphoplasmacytic lymphoma/Waldenström’s macroglobulinaemia in Japan and Taiwan population-based cancer registries, 1996–2003. Int J Cancer. 2014;134(1):174–180.
- Brandefors L, Melin B, Lindh J, et al. Prognostic factors and primary treatment for Waldenstro€m macroglobulinemia – a Swedish Lymphoma Registry study. Br J Haematol. 2018;183(4):564–577.
- Kristinsson SY, Bjo€Rkholm M, Goldin LR, et al. Risk of lymphoproliferative disorders among first-degree relatives of lymphoplasma- cytic lymphoma/Waldenstro€m macroglobuline- mia patients: a population-based study in Sweden. Blood. 2008;112(8):3052–3056.
- Buske C, Sadullah S, Kastritis E, et al. Treatment and outcome patterns in European patients with Waldenström’s macroglobulinaemia: a large, observational, retrospective chart review. Lancet Haematol. 2018;5(7):e299–e309.
- Buske C, Hoster E, Dreyling M, et al. The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: results of a randomized trial of the German Low-Grade Lymphoma Study Group (GLSG). Leukemia. 2009;23(1):153–161.
- Treon SP, Meid K, Gustine J, et al. Long-term follow-up of ibrutinib monotherapy in symptomatic, previously treated patients with Waldenstro ¨m macroglobulinemia. J Clin Oncol. 2021;39(6):565–575.
- Morel P, Monconduit M, Jacomy D, et al. Patients with the description of a new scoring system and its validation on 253 other patients. Blood. 2000;96(3):852–858.
- Treon SP. How I treat Waldenstro€m macroglobulinemia. Blood. 2015;126(6):721–732.